Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-escalation, Bi-weekly Phase I Clinical Trial in Treating Patients With Recurrent or Metastatic Cervical Cancer

NCT03676959 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.

NCT NCT03676959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03676959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-escalation, Bi-weekly Phase I Clinical Trial in Treating Patients With Recurrent or Metastatic Cervical Cancer
Lead sponsor
Lee's Pharmaceutical Limited
Phase
Phase 1
Overall status
Unknown status
Start date
August 16, 2018
Completion date
October 15, 2022
Enrollment
101 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer